MGX Stock Overview
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Metagenomi, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$7.04 |
52 Week High | US$12.74 |
52 Week Low | US$6.50 |
Beta | 0 |
1 Month Change | -34.94% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -31.72% |
Recent News & Updates
Recent updates
Shareholder Returns
MGX | US Biotechs | US Market | |
---|---|---|---|
7D | 4.3% | 0.5% | -0.7% |
1Y | n/a | 1.2% | 22.8% |
Return vs Industry: Insufficient data to determine how MGX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how MGX performed against the US Market.
Price Volatility
MGX volatility | |
---|---|
MGX Average Weekly Movement | 10.7% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.7% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MGX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MGX's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2016 | 236 | Brian Thomas | www.metagenomi.co |
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company’s genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies.
Metagenomi, Inc. Fundamentals Summary
MGX fundamental statistics | |
---|---|
Market cap | US$263.06m |
Earnings (TTM) | -US$68.25m |
Revenue (TTM) | US$44.76m |
5.9x
P/S Ratio-3.9x
P/E RatioIs MGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MGX income statement (TTM) | |
---|---|
Revenue | US$44.76m |
Cost of Revenue | US$94.40m |
Gross Profit | -US$49.65m |
Other Expenses | US$18.61m |
Earnings | -US$68.25m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.82 |
Gross Margin | -110.93% |
Net Profit Margin | -152.50% |
Debt/Equity Ratio | 0% |
How did MGX perform over the long term?
See historical performance and comparison